Dr. Abou-Alfa on Trials Investigating Immunotherapy in HCC

Ghassan K. Abou-Alfa, MD
Published: Wednesday, Jun 21, 2017



Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).

The field of immunotherapy is moving very rapidly based on solid data, explains Abou-Alfa. Preclinical data demonstrate that evidence is there regarding PD-1/PD-L1 expression as well as other markers for checkpoint inhibitors.

The CheckMate-040 trial, which is investigating nivolumab (Opdivo) in patients with HCC, demonstrated that nearly 260 patients had a continued response rate of 20%.
 


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).

The field of immunotherapy is moving very rapidly based on solid data, explains Abou-Alfa. Preclinical data demonstrate that evidence is there regarding PD-1/PD-L1 expression as well as other markers for checkpoint inhibitors.

The CheckMate-040 trial, which is investigating nivolumab (Opdivo) in patients with HCC, demonstrated that nearly 260 patients had a continued response rate of 20%.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x